TAMPA, FL / ACCESS Newswire / August 6, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) (&#34;DataMeds AI,&#34; &#34;DataMEDS,&#34; or the &#34;Company&#34;), a Health IT company leveraging its artificial intelligence platform

<p><strong id="dateline">TAMPA, FL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 6, 2026 / </strong>DataMeds AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MEDS">MEDS</a>) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx&#8482; and blockchain-enabled smart contracts platform PharmacyChain&#8482; to provide integrated solutions for the compliant monetization of health data by market participants, today reiterated the August 7, 2026 record date for the 50:1 token to stock ratio for the Dream Bowl Meme Coin token (to DataMEDS common shares.</p><p>The official platform for Dream Bowl Meme Coin tokens is <a rel="nofollow" href="https://pr.report/osox">https://www.biconomy.com/exchange/DREAM1_USDT</a>. Dream Bowl Meme Coin token is not authorized to trade on CoinBase <a rel="nofollow" href="https://pr.report/osoy">https://www.coinbase.com/price/dream-bowl-meme-coin-solana-b067b9fd</a>.</p><p>The Company intends to pursue fail to deliver notices aggressively.</p><p><strong>About DataMeds AI, Inc.</strong></p><p>DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx&#8482; and blockchain-enabled smart contracts platform PharmacyChain&#8482; into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: the Company's non-binding letter of intent to acquire a controlling interest in Tollo Health, LLC, and the anticipated timing, structure, terms and completion of that transaction; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.</p><p>Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others: the risk that the Company's proposed acquisition of a controlling interest in Tollo Health, LLC may not be completed on the anticipated terms or timeline, or at all, including because the parties have not yet executed definitive agreements; the risk that the proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to the regulatory classification and marketing claims applicable to dietary supplements and medical foods, including Tollovid and Galactovid; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.</p><p>Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p><strong>DataMeds AI Media Contact</strong><br/>James Lambert, Vice President<br/>Rubenstein Public Relations<br/>Phone: 212.805.3024<br/>Email: <a rel="nofollow" href="mailto:jlambert@rubensteinpr.com">jlambert@rubensteinpr.com</a></p><p><strong>DataMeds AI Investor Contact</strong><br/>Investor Relations: <a rel="nofollow" href="mailto:IR@wellgisticshealth.com">IR@wellgisticshealth.com</a></p><p style="text-align:center;">###</p><p><strong>SOURCE: </strong>DataMEDS AI, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/datameds-ai-reiterates-50-1-dream-bowl-meme-coin-token-to-common-shar-1203422'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1203422" width="0" height="0"/>

MEDS

DataMeds AI Reiterates 50:1 Dream Bowl Meme Coin Token to Common Shares Dividend Ratio with an August 7, 2026 Record Date

DataMeds AI reiterates 50-to-1 Dream Bowl Coin conversion to MEDS stock

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>TAMPA, FL / ACCESS Newswire / August 6, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) (&amp;#34;DataMeds AI,&amp;#34; &amp;#34;DataMEDS,&amp;#34; or the &amp;#34;Company&amp;#34;), a Health IT company leveraging its artificial intelligence platform</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>DataMeds AI confirms the August 7, 2026 record date for a 50:1 Dream Bowl Meme Coin to MEDS share conversion, signaling potential dilution if tokens convert. The release cites non-binding LOIs and possible deals with multiple partners, while highlighting execution, regulatory, and liquidity uncertainties that could influence MEDS valuation and funding strategy in the near term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Reiterates Aug 7, 2026 record date for 50:1 Dream Bowl Coin to MEDS shares.</li><li>Dream Bowl Coin platform on biconomy; Coinbase authorization not present.</li><li>Company intends to pursue fail-to-deliver notices aggressively.</li><li>Non-binding LOI to acquire controlling interest in Tollo Health; other deals discussed.</li><li>Forward-looking statements cover AI, blockchain, telemedicine growth and regulatory risks.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>DataMeds AI, Inc. (MEDS)</strong>: Core MEDS business relies on EinsteinRx and PharmacyChain; token conversion could affect equity.</li><li><strong>Tollo Health, LLC</strong>: Non-binding LOI to acquire controlling interest; potential strategic leverage.</li><li><strong>DataVault AI Inc.</strong>: Possible transaction discussed; impact depends on terms and financing.</li><li><strong>Scilex Holding Company</strong>: Possible deal partner; portfolio and integration risks prominent.</li><li><strong>EOS Holdings</strong>: Potential transaction; execution risk and regulatory considerations noted.</li><li><strong>HealthBridge Advisors</strong>: Part of potential transaction framework; details not disclosed.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Fits as the piece centers on token-linked corporate actions, potential M&amp;A activity, and strategic partnerships affecting MEDS’s capital structure and liquidity.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>50:1 token-to-stock conversion could dilute existing MEDS holders.</li><li>Dream Bowl Coin availability and exposure may affect liquidity and sentiment.</li><li>Possible M&amp;A and strategic partnerships could create near-term volatility.</li><li>Regulatory and crypto-market risk on healthcare tech could weigh on MEDS.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>August 7, 2026 record date for Dream Bowl Meme Coin to MEDS shares.</li><li>50:1 token-to-stock ratio for the Dream Bowl Coin conversion.</li><li>Dream Bowl Coin platform listed as biconomy; DREAM1_USDT; Coinbase not authorized.</li><li>Not authorized to trade on Coinbase; forward-looking statements included.</li><li>Tampa, Florida-based DataMeds AI, Inc. emphasizes AI and blockchain platforms.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution risk from token conversion may pressure MEDS; monitor 2H2026 deal progress.</p>
  </section>
</section>


<p><strong id="dateline">TAMPA, FL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 6, 2026 / </strong>DataMeds AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MEDS">MEDS</a>) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx&#8482; and blockchain-enabled smart contracts platform PharmacyChain&#8482; to provide integrated solutions for the compliant monetization of health data by market participants, today reiterated the August 7, 2026 record date for the 50:1 token to stock ratio for the Dream Bowl Meme Coin token (to DataMEDS common shares.</p><p>The official platform for Dream Bowl Meme Coin tokens is <a rel="nofollow" href="https://pr.report/osox">https://www.biconomy.com/exchange/DREAM1_USDT</a>. Dream Bowl Meme Coin token is not authorized to trade on CoinBase <a rel="nofollow" href="https://pr.report/osoy">https://www.coinbase.com/price/dream-bowl-meme-coin-solana-b067b9fd</a>.</p><p>The Company intends to pursue fail to deliver notices aggressively.</p><p><strong>About DataMeds AI, Inc.</strong></p><p>DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx&#8482; and blockchain-enabled smart contracts platform PharmacyChain&#8482; into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: the Company's non-binding letter of intent to acquire a controlling interest in Tollo Health, LLC, and the anticipated timing, structure, terms and completion of that transaction; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.</p><p>Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others: the risk that the Company's proposed acquisition of a controlling interest in Tollo Health, LLC may not be completed on the anticipated terms or timeline, or at all, including because the parties have not yet executed definitive agreements; the risk that the proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to the regulatory classification and marketing claims applicable to dietary supplements and medical foods, including Tollovid and Galactovid; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.</p><p>Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p><strong>DataMeds AI Media Contact</strong><br/>James Lambert, Vice President<br/>Rubenstein Public Relations<br/>Phone: 212.805.3024<br/>Email: <a rel="nofollow" href="mailto:jlambert@rubensteinpr.com">jlambert@rubensteinpr.com</a></p><p><strong>DataMeds AI Investor Contact</strong><br/>Investor Relations: <a rel="nofollow" href="mailto:IR@wellgisticshealth.com">IR@wellgisticshealth.com</a></p><p style="text-align:center;">###</p><p><strong>SOURCE: </strong>DataMEDS AI, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/datameds-ai-reiterates-50-1-dream-bowl-meme-coin-token-to-common-shar-1203422'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1203422" width="0" height="0"/>

DataMeds AI confirms the August 7, 2026 record date for a 50:1 Dream Bowl Meme Coin to MEDS share conversion, signaling potential dilution if tokens convert. The release cites non-binding LOIs and possible deals with multiple partners, while highlighting execution, regulatory, and liquidity uncertainties that could influence MEDS valuation and funding strategy in the near term.

News insight

DataMeds AI Reiterates 50:1 Dream Bowl Meme Coin Token to Common Shares Dividend Ratio with an August 7, 2026 Record Date

AI summary

Sentiment rationale

Key facts

Corporate Developments